Early Investigator Grant Opportunity The Foundation for Sarcoidosis Research (FSR) is seeking proposals from US-based early-stage investigators for a grant that provides support for a collaborative and translational research project that will positively impact...
Xentria Inc. has recently announced they received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for their intravenous TNF-inhibitor, XTMAB-16. The FDA grants orphan status to drugs being developed to treat those with rare diseases. This...
Program supports specialized skill development of early-career physicians and researchers interested in studying sarcoidosis CHICAGO, Dec. 17, 2020 /PRNewswire/ — The Foundation for Sarcoidosis Research (FSR) is pleased to announce the opening of a new...
This is a recording from FSR’s COVID-19 Q&A with Dr. Divya Patel on December 10, 2020. Topics covered include how COVID-19 may affect sarcoidosis patients, the new vaccines*, and holiday safety. *Please see below for a note from Dr. Divya Patel as a followup...
